A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments.
This patient received the treatment in a clinical trial led by Steven A. Rosenberg, M.D., Ph.D., chief of the Surgery Branch at NCI’s Center for Cancer Research (CCR), and the findings were published June 4, 2018 in Nature Medicine. NCI is part of the National Institutes of Health.
“We’ve developed a high-throughput method to identify mutations present in a cancer that are recognized by the immune system,” Dr. Rosenberg said. “This research is experimental right now. But because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is in a sense a blueprint we can use for the treatment of many types of cancer.”
The new immunotherapy approach is a modified form of adoptive cell transfer (ACT). ACT has been effective in treating melanoma, which has high levels of somatic, or acquired, mutations. However, it has been less effective with some common epithelial cancers, or cancers that start in the lining of organs, that have lower levels of mutations, such as stomach, esophageal, ovarian, and breast cancers.
In an ongoing phase 2 clinical trial, the investigators are developing a form of ACT that uses tumor-infiltrating lymphocytes (TILs) that specifically target tumor cell mutations to see if they can shrink tumors in patients with these common epithelial cancers. As with other forms of ACT, the selected TILs are grown to large numbers in the laboratory and are then infused back into the patient (who has in the meantime undergone treatment to deplete remaining lymphocytes) to create a stronger immune response against the tumor.
A patient with metastatic breast cancer came to the trial after receiving multiple treatments, including several chemotherapy and hormonal treatments, that had not stopped her cancer from progressing. To treat her, the researchers sequenced DNA and RNA from one of her tumors, as well as normal tissue to see which mutations were unique to her cancer, and identified 62 different mutations in her tumor cells.
The researchers then tested different TILs from the patient to find those that recognized one or more of these mutated proteins. TILs recognized four of the mutant proteins, and the TILs then were expanded and infused back into the patient. She was also given the checkpoint inhibitor pembrolizumab to prevent the possible inactivation of the infused T cells by factors in the tumor microenvironment. After the treatment, all of this patient’s cancer disappeared and has not returned more than 22 months later.
“This is an illustrative case report that highlights, once again, the power of immunotherapy,” said Tom Misteli, Ph.D., director of CCR at NCI. “If confirmed in a larger study, it promises to further extend the reach of this T-cell therapy to a broader spectrum of cancers.”
Investigators have seen similar results using mutation-targeted TIL treatment for patients in the same trial with other epithelial cancers, including liver cancer and colorectal cancer. Dr. Rosenberg explained that results like this in patients with solid epithelial tumors are important because ACT has not been as successful with these kinds of cancers as with other types that have more mutations.
He said the “big picture” here is this kind of treatment is not cancer-type specific. “All cancers have mutations, and that’s what we’re attacking with this immunotherapy,” he said. “It is ironic that the very mutations that cause the cancer may prove to be the best targets to treat the cancer.”
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapyon May 6, 2021 at 12:27 pm
Li et al. identify LIMIT as a lncRNA that modulates MHC-I expression through HSP90 and HSF1, thereby regulating antitumour immune response and the efficacy of immunotherapy.
- The Future of Cancer Immunotherapy Lies in Combinational Approacheson May 6, 2021 at 11:20 am
Arsen Osipov, MD, discusses the potential for ongoing research with immunotherapeutic approaches in gastrointestinal malignancies, including CAR T-cell therapy, bispecific T-cell engagers, and ...
- The Oncolytic Virus Immunotherapy Market To Grow With Innovations Brought By Top Key-Players On The Platteron May 6, 2021 at 10:10 am
The Oncolytic Virus Immunotherapy Market report by Persistence Market Research focuses on the healthcare trends to be pondered about in the upcoming period. When the world at large is gripped with ...
- University Hospitals first in Ohio to treat patients with two FDA approved CAR T cancer therapieson May 6, 2021 at 9:04 am
Oncologists at University Hospitals (UH) have two new powerful tools in the fight against cancer following the announcement that Abecma & Breyanzi, from Bristol Myers Squibb (BMS), are currently being ...
- Uncovering epigenetic mechanisms underlying cancer developmenton May 6, 2021 at 5:19 am
Northwestern Medicine studies published in Nature Cell Biology and Molecular Cell are improving the understanding of epigenetic mechanisms in cancer development and progression, as well as pinpointing ...
- Cue Biopharma to Present at the 2021 Frontiers in Cancer Immunotherapy Conferenceon May 6, 2021 at 5:03 am
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly ...
- Microneedles for cancer immunotherapy may lead to minimal invasiveness, side effectson May 5, 2021 at 9:55 pm
A recent study from the University of Helsinki monitors the breakthrough progresses in the development of microneedles for immunotherapy and discusses the challenges regarding their production.
- Specific Cancer Immunotherapy Drugs Market Recent Trends, Growth Factors, Business Opportunities 2021-2025on May 5, 2021 at 11:50 am
The Specific Cancer Immunotherapy Drugs Market exhibits comprehensive information that is a valuable source of insightful data for business strategists during the decade 2015-2025. On the basis of ...
- New Research Raises the Question: When Is the Best Time to Give Patients With Lung Cancer Immunotherapy?on May 4, 2021 at 12:30 pm
New data from the Checkmate-816 study suggests that treating patients with lung cancer with immunotherapy before surgery improves survival.
via Bing News